BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33581582)

  • 1. Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies.
    Sundström C; Hollander P
    Immunobiology; 2021 Mar; 226(2):152069. PubMed ID: 33581582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
    Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
    Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases.
    Abdulla M; Sundström C; Lindskog C; Hollander P
    Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-infected cells in IgG4-related lymphadenopathy with comparison with extranodal IgG4-related disease.
    Takeuchi M; Sato Y; Yasui H; Ozawa H; Ohno K; Takata K; Gion Y; Orita Y; Tachibana T; Itoh T; Asano N; Nakamura S; Swerdlow SH; Yoshino T
    Am J Surg Pathol; 2014 Jul; 38(7):946-55. PubMed ID: 24705309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.
    Grywalska E; Smarz-Widelska I; Korona-Głowniak I; Mertowski S; Gosik K; Hymos A; Ludian J; Niedźwiedzka-Rystwej P; Roliński J; Załuska W
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
    Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
    Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
    Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
    Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Epstein-Barr virus-infected cells in benign lymphadenopathy of patients seropositive for human immunodeficiency virus.
    Brousset P; Schlaifer D; Roda D; Massip P; Marchou B; Delsol G
    Hum Pathol; 1996 Mar; 27(3):263-8. PubMed ID: 8600041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of Epstein-Barr virus in systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis) with associated lymphadenopathy: a study of 49 cases.
    Kojima M; Motoori T; Itoh H; Shimizu K; Iijima M; Tamaki Y; Murayama K; Ohno Y; Yoshida K; Masawa N; Nakamura S
    Int J Surg Pathol; 2005 Jul; 13(3):273-8. PubMed ID: 16086083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.